🔎 Trials Near Me

Home › Cancro del polmone non a piccole cellule › New Mexico

Studi clinici su Cancro del polmone non a piccole cellule nello stato di New Mexico

22 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi nello stato di New Mexico.

Città nello stato di New Mexico

Testo ufficiale dello studio (inglese)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • University of New Mexico Cancer Center, Albuquerque
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center, Rio Rancho
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  • University of New Mexico - Comprehensive Cancer Center, Albuquerque
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07365319

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • University of New Mexico Cancer Center, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
  • Christus St. Vincent Regional Medical Center, Santa Fe
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07144280

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
  • CHRISTUS St. Vincent Regional Cancer Center, Santa Fe
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • New Mexico Oncology Hematology Consultants, Ltd, Albuquerque
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07489066

Pan-tumor MRD Study

  • San Juan Oncology Associates, Farmington
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06605404

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

  • New Mexico Oncology Hematology Consultants, Albuquerque
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07028489

An External Control Arm Study in Non-Small Cell Lung Cancer

  • New Mexico Oncology Hematology Consultants, Albuquerque
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174388

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of New Mexico Comprehensive Cancer Center, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07291037

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  • University of New Mexico Comprehensive Cancer Center ( Site 0135), Albuquerque
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06422143

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • University of New Mexico Cancer Center, Albuquerque
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2026 · NCT05642572

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • University of New Mexico Cancer Center, Albuquerque
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Lovelace Medical Center-Saint Joseph Square, Albuquerque
  • University of New Mexico Cancer Center, Albuquerque
  • Lovelace Women's Hospital, Albuquerque
  • e altri 3
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • Presbyterian Kaseman Hospital (site 208), Albuquerque
In reclutamentoFase 1/2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 11 dic 2025 · NCT03556228

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Albuquerque
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774

BostonGene and Exigent Genomic INsight Study

  • New Mexico Cancer Center, Albuquerque
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 feb 2025 · NCT06272864

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.